INS and metabolic syndrome: Although speculative, prior preclinical evidence [69,73] has suggested that angiotensin receptor antagonists may improve dyslipidemia by reducing triglycerides through the activation of peroxisome proliferator-activated receptor (PPAR) gamma, which regulates lipid metabolism [69] and influences the expression of PPARgamma target genes involved in carbohydrate and lipid metabolism reducing glucose, insulin, and triglyceride levels [73].